Fintel reports that on March 4, 2025, Needham downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy to ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The clinical-stage ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

PLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).